Skip to main content

CORRECTION article

Front. Endocrinol., 27 April 2022
Sec. Pituitary Endocrinology
Volume 13 - 2022 | https://doi.org/10.3389/fendo.2022.899616

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

This article is a correction to:

  1. Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

    1. Read original article
Rosario PivonelloRosario Pivonello1Irina BancosIrina Bancos2Richard A. FeeldersRichard A. Feelders3Atil Y. KargiAtil Y. Kargi4Janice M. KerrJanice M. Kerr5Murray B. GordonMurray B. Gordon6Cary N. MariashCary N. Mariash7Massimo TerzoloMassimo Terzolo8Noel EllisonNoel Ellison9Andreas G. Moraitis*Andreas G. Moraitis10*
  • 1Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy
  • 2Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, United States
  • 3Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, Netherlands
  • 4Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, FL, United States
  • 5Department of Endocrinology, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, United States
  • 6Allegheny Neuroendocrinology Center, Allegheny General Hospital, Pittsburgh, PA, United States
  • 7Methodist Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States
  • 8Department of Clinical and Biological Sciences, Internal Medicine 1 − San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy
  • 9Trialwise, Inc, Houston, TX, United States
  • 10Corcept Therapeutics, Menlo Park, CA, United States

A Corrigendum on
Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

By Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N, Moraitis AG (2021) Front Endocrinol. 12:662865. doi: .10.3389/fendo.2021.662865

In the original article, there was an error. In the ACTH-dependent CS group, the median (min) change in ACTH from baseline to last observed visit in conventional units (pg/mL) should be 16.8 (-70.9) instead of 0.8 (-3.4).

A correction has been made to Results, “Hormone Changes,” paragraph 1:

“Among all patients with ACTH-dependent CS (n = 26 with values at last visit), the median (min, max) change from baseline to last observed visit was 3.7 (-15.6, 20.0) pmol/L [16.8 (-70.9, 90.9) pg/mL] (p = 0.003) for plasma ACTH…”

A correction has been made to Discussion, paragraph 6:

“In the present study, the respective median changes from baseline in UFC and ACTH were 4.0 nmol/d (1.4 μg/24 h) and 3.7 pmol/L (16.8 pg/mL) in the ACTH-dependent CS group…”

In the original article, there was an error. A negative sign was omitted from the min LNSC value in conventional units (µg/dL). Instead of 1.1, it should be -1.1 µg/dL.

A correction has been made to Results, “Hormone Changes,” paragraph 1:

“… -0.33 (-30.6, 47.7) nmol/L [-0.01 (-1.1, 1.7) µg/dL] (p = 0.815) for LNSC…”

The authors apologize for the errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: clinical trial, cortisol, Cushing syndrome, glucocorticoid, hypercortisolism, hyperglycemia, hypertension, relacorilant

Citation: Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, Mariash CN, Terzolo M, Ellison N and Moraitis AG (2022) Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front. Endocrinol. 13:899616. doi: 10.3389/fendo.2022.899616

Received: 18 March 2022; Accepted: 29 March 2022;
Published: 27 April 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Pivonello, Bancos, Feelders, Kargi, Kerr, Gordon, Mariash, Terzolo, Ellison and Moraitis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Andreas G. Moraitis, amoraitis@corcept.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.